CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges.

Arsenijevic, Tatjana; Coulonval, Katia; Raspé, Eric; Demols, Anne; Roger, Pierre P; Van Laethem, Jean-Luc

Arsenijevic, Tatjana; Coulonval, Katia; Raspé, Eric; Demols, Anne; Roger, Pierre P; Van Laethem, Jean-Luc.

Afiliação

Arsenijevic T; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Coulonval K; Department of Gastroenterology, Hepatology and Digestive Oncology, HUB Bordet Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Raspé E; Institute of Interdisciplinary Research (Iribhm), ULB-Cancer Research Center (U-crc), Université Libre de Bruxelles, Campus Erasme, Route de Lennik 808, 1070 Brussels, Belgium.
Demols A; Institute of Interdisciplinary Research (Iribhm), ULB-Cancer Research Center (U-crc), Université Libre de Bruxelles, Campus Erasme, Route de Lennik 808, 1070 Brussels, Belgium.
Roger PP; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Van Laethem JL; Department of Gastroenterology, Hepatology and Digestive Oncology, HUB Bordet Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.

Cancers (Basel) ; 15(3)2023 Feb 03.

Article em En | MEDLINE | ID: mdl-36765923

Palavras-chave

CDK4/6 inhibitors; cholangiocarcinoma; pancreatic ductal adenocarcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google